These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 26428461

  • 1. A stapled peptide antagonist of MDM2 carried by polymeric micelles sensitizes glioblastoma to temozolomide treatment through p53 activation.
    Chen X, Tai L, Gao J, Qian J, Zhang M, Li B, Xie C, Lu L, Lu W, Lu W.
    J Control Release; 2015 Nov 28; 218():29-35. PubMed ID: 26428461
    [Abstract] [Full Text] [Related]

  • 2. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid) micelle enhances paclitaxel anti-glioblastoma effect.
    Zhan C, Gu B, Xie C, Li J, Liu Y, Lu W.
    J Control Release; 2010 Apr 02; 143(1):136-42. PubMed ID: 20056123
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo.
    Zhan C, Wei X, Qian J, Feng L, Zhu J, Lu W.
    J Control Release; 2012 Jun 28; 160(3):630-6. PubMed ID: 22410115
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Decitabine nanoconjugate sensitizes human glioblastoma cells to temozolomide.
    Cui Y, Naz A, Thompson DH, Irudayaraj J.
    Mol Pharm; 2015 Apr 06; 12(4):1279-88. PubMed ID: 25751281
    [Abstract] [Full Text] [Related]

  • 8. Temozolomide-loaded photopolymerizable PEG-DMA-based hydrogel for the treatment of glioblastoma.
    Fourniols T, Randolph LD, Staub A, Vanvarenberg K, Leprince JG, Préat V, des Rieux A, Danhier F.
    J Control Release; 2015 Jul 28; 210():95-104. PubMed ID: 25982679
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy.
    Li C, Shen J, Wei X, Xie C, Lu W.
    J Drug Target; 2012 Apr 28; 20(3):264-71. PubMed ID: 22233211
    [Abstract] [Full Text] [Related]

  • 11. Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy.
    Song S, Mao G, Du J, Zhu X.
    Drug Deliv; 2016 May 28; 23(4):1404-8. PubMed ID: 26203687
    [Abstract] [Full Text] [Related]

  • 12. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M, Diesler K, Majhen D, Steigerwald C, Berte N, Freund H, Stojanović N, Kaina B, Osmak M, Ambriović-Ristov A, Tomicic MT.
    Oncotarget; 2017 Apr 25; 8(17):27754-27771. PubMed ID: 27487141
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
    Daniele S, La Pietra V, Piccarducci R, Pietrobono D, Cavallini C, D'Amore VM, Cerofolini L, Giuntini S, Russomanno P, Puxeddu M, Nalli M, Pedrini M, Fragai M, Luchinat C, Novellino E, Taliani S, La Regina G, Silvestri R, Martini C, Marinelli L.
    Eur J Pharmacol; 2021 Apr 15; 897():173936. PubMed ID: 33581134
    [Abstract] [Full Text] [Related]

  • 15. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
    Liu M, Li C, Pazgier M, Li C, Mao Y, Lv Y, Gu B, Wei G, Yuan W, Zhan C, Lu WY, Lu W.
    Proc Natl Acad Sci U S A; 2010 Aug 10; 107(32):14321-6. PubMed ID: 20660730
    [Abstract] [Full Text] [Related]

  • 16. Delivery of a drug cache to glioma cells overexpressing platelet-derived growth factor receptor using lipid nanocarriers.
    Miller K, Dixit S, Bredlau AL, Moore A, McKinnon E, Broome AM.
    Nanomedicine (Lond); 2016 Mar 10; 11(6):581-95. PubMed ID: 27003178
    [Abstract] [Full Text] [Related]

  • 17. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
    Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Purmal AA, Gudkov AV, Plunkett RJ.
    Neuro Oncol; 2017 Feb 01; 19(2):186-196. PubMed ID: 27370399
    [Abstract] [Full Text] [Related]

  • 18. Combined inhibition of AKT/mTOR and MDM2 enhances Glioblastoma Multiforme cell apoptosis and differentiation of cancer stem cells.
    Daniele S, Costa B, Zappelli E, Da Pozzo E, Sestito S, Nesi G, Campiglia P, Marinelli L, Novellino E, Rapposelli S, Martini C.
    Sci Rep; 2015 Apr 21; 5():9956. PubMed ID: 25898313
    [Abstract] [Full Text] [Related]

  • 19. Study on Therapeutic Action and Mechanism of TMZ Combined with RITA Against Glioblastoma.
    Wu Q, Cao Z, Xiao W, Zhu L, Xie Q, Li L, Zhang B, Zhao W.
    Cell Physiol Biochem; 2018 Apr 21; 51(6):2536-2546. PubMed ID: 30562758
    [Abstract] [Full Text] [Related]

  • 20. Integrin α5β1 plays a critical role in resistance to temozolomide by interfering with the p53 pathway in high-grade glioma.
    Janouskova H, Maglott A, Leger DY, Bossert C, Noulet F, Guerin E, Guenot D, Pinel S, Chastagner P, Plenat F, Entz-Werle N, Lehmann-Che J, Godet J, Martin S, Teisinger J, Dontenwill M.
    Cancer Res; 2012 Jul 15; 72(14):3463-70. PubMed ID: 22593187
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.